Clinical Trial Update: Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable) [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 clinical trial evaluated bi-weekly pemetrexed plus cisplatin in patients with urothelial cancer (metastatic, locally advanced, or non-resectable)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Urologic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2009-06-17